GRI Bio Raises $13.9M In Gross Proceeds Since Start Of 2024; Funds Expected To Extend Cash Runway Into Mid-Q1 2025, Supporting Interim Data From Phase 2a Study Of GRI-0621 For Idiopathic Pulmonary Fibrosis (IPF) Treatment

Benzinga10/24 20:33

Top Midday Decliners

MT Newswires10/23 02:12

Dow Falls Over 150 Points; General Motors Tops Q3 Views

Benzinga10/22 22:03

Wall Street Set to Open Lower as Investors Await Earnings Report, Harker Speech

MT Newswires10/22 21:17

GRI Bio GRI Warrants Exercised; Immunic IMUX Phase 3 IDMC Recommendation

BioPharmCatalyst10/22 20:21

Investors Await Earnings Reports as US Futures Move Lower Tuesday Pre-Bell

MT Newswires10/22 20:14